BOOK A DEMO

"*" indicates required fields

Agreement*
This field is for validation purposes and should be left unchanged.

* Required fields
Contact Us
About us

Simplifying detection.
Saving lives.

Lung cancer is the #1 cancer killer in America and usually goes undetected until it’s too late. When found early, survival rates are dramatically higher. Riverain Technologies is dedicated to the early detection of lung cancer and creating better outcomes for patients everywhere.

Woman radiologist viewing lung CT scans on video monitor

AI imaging solutions for the early, efficient detection of lung disease

Riverain ClearRead solutions significantly improve a clinician’s ability to accurately and efficiently detect disease in thoracic (lung) CT and XR images and more successfully address the challenges of early detection of lung disease. Powered by machine learning and advanced modeling, the patented, FDA-cleared ClearRead software tools are deployed in the clinic or the cloud and are powered by the most advanced AI methods available to the medical imaging market. While the benefit for patients can be life changing, the advantages for radiologists are equally substantial. Battling growing workloads and less time, ClearRead solutions allow clinicians to complete more reads faster – saving valuable time without sacrificing performance.

Core Values

Mission

To save lives through the early detection, diagnosis, and management of lung disease.


Vision

To be recognized as a transformative leader in the thoracic sciences.

Clinical advisors with a vision for the future

Jared Christensen portrait
Jared Christensen, MD, MBA

Dr. Jared Christensen is vice chair of strategy of the Duke University Department of Radiology and director of the Duke Lung Cancer Screening Program. He currently serves as chair of the American College of Radiology Lung-RADS Committee. Dr. Christensen’s professional interests in AI focus on finding solutions that decrease variability, increase efficiency, and improve patient outcomes.

Portraits of Jonathan-Chung MD
Jonathan Chung, MD

Dr. Jonathan Chung, professor of radiology, chief, section of thoracic radiology, and chief quality officer at the University of Chicago Medicine, specializes in cardiopulmonary imaging. He analyzes and interprets chest radiographs and CT scans for thoracic diseases. He also has expertise in interstitial lung disease, occupational lung disease, nontuberculous mycobacterial pneumonia and diseases of the large and small airways. He has authored over 140 peer-reviewed articles that have been published in scientific journals, co-authored five book chapters and five books that focus on chest diagnostics.

Charles White portrait
Charles White, MD

Dr. Charles White has been on the Riverain advisory board since 2013, and is Professor of Radiology and Medicine at the University of Maryland Medical Center. Dr. White has a special interest in the diagnosis and staging of lung cancer and cardiac CT imaging. Dr. White was named one of Baltimore Magazine’s 2010 “Top Docs” for General Diagnostic Radiology.

Meet the Leadership Team

Steve Worrell

Steve became CEO of Riverain Technologies in 2013 after joining Riverain as Vice President of Research in 2007.  Prior to joining Riverain Technologies, he was a principal developer of iCAD’s SecondLook mammography computer aided detection (CAD) system.  His primary focus was the development of iCAD’s microcalcification detection system.  His earlier career included development of model based vision systems for military applications using synthetic aperture radar.   Since joining Riverain Technologies his focus has been on developing, marketing, and commercializing Riverain’s X-ray and CT product lines.

Jason Knapp

Jason leads the research team in the development of advanced AI applications for medical imaging. He has been the principal developer of 7 FDA-approved products, which are used throughout the world, touching millions of lives each year.

Ofer Pinhasi

Ofer Pinhasi has been Chief Product Officer for Riverain Technologies since 2020. In this role, he leads the development and deployment of Riverain Technologies’ products in world markets, establishing governance processes, and leading the strategic planning effort to achieve business goals. Prior to joining Riverain, Ofer’s medical device experience spans artificial intelligence and CT/NM scanner design and production at GE and Philips.

Proudly partnering with these industry leaders

Unlike many AI solutions, Riverain technology is verifed, validated, and FDA-cleared. Our technology has been substantiated by peer-reviewed articles, third party studies, and reference accounts. That’s why so many respected healthcare organizations have partnered with Riverain Technologies, allowing potential customers easy access to the power of the ClearRead Suite with the initial purchase of their imaging devices. You can contact these partners directly or work with a Riverain representative for more information.